A NEW test could help patients with advanced bowel cancer get the best treatment for their disease, according to a Cancer Research UK clinical trial published today (Thursday) in JAMA Oncology*.
The trial** - which was run from St. James's University Hospital and University of Leeds - studied almost 1,200 patients at hospitals all over the UK with advanced bowel cancer whose first chemotherapy treatment had stopped working and who were starting a second chemotherapy treatment called irinotecan.
In the trial, each patient had their cancer tested for a gene called RAS. If there were no faults in the gene, they went on to receive irinotecan either alone or together with a new targeted cancer drug called panitumumab. The research showed that some patients benefited from adding the new drug but others did not and further studies were carried out to find out why.
Tumour samples from 323 of the trial patients were tested for levels of two proteins - called AREG and EREG - which are produced by some cancer cells to help them grow. Panitumumab blocks these proteins, stopping tumours developing.
The team showed that for patients with high levels of the proteins, the drug combination stopped cancer growth for nearly twice as long as irinotecan alone - an average of eight months compared with four and a half months. But the drug did not work for patients with low levels of the proteins.
Study author Dr Jenny Seligmann, Cancer Research UK clinical trial fellow from the University of Leeds, said: "These results are very promising. Our task now is to develop a fast and reliable test for the two proteins that can be offered to patients before they start treatment, to help select the right drugs to use.
"Thanks to research we now have new cancer drugs that work in very specific ways, targeting individual rogue molecules in cancer cells. These drugs can be of enormous help to some patients, but not others - so as well as developing new treatments it is vital that we find the right way to select the best treatment for each individual patient. This will help patients to have more time with their loved ones, and to avoid the distress of going through ineffective treatment."
Around 41,000 people are diagnosed with bowel cancer and around 16,000 people die from the disease in the UK every year.
Nell Barrie, Cancer Research UK's senior science information manager, said: "Bowel cancer is the second biggest cancer killer so it's vital that we find better ways to tackle this disease once it's spread. One of the most important ways Cancer Research UK helps to improve treatments and make them kinder is by investigating exactly who will or won't benefit. This research may lead to new options for patients with advanced bowel cancer, which can be hard to treat - the next step is to find out if this can be used by doctors in the clinic."
###
For media enquiries contact Emily Head in the Cancer Research UK press office on 020 3469 6189 or, out of hours, on 07050 264 059.
Notes to editor:
* Seligmann et al. Combined epiregulin and amphiregulin expression levels as a predictive biomarker for panitumumab in RAS-wt advanced colorectal cancer. JAMA Oncology.
** For more information about the PICCOLO trial please visit: http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-looking-at-panitumumab-irinotecan-and-ciclosporin-for-advanced-bowel-cancer
About Cancer Research UK
- Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
- Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
- Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
- Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
- Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that 3 in 4 people will survive their cancer for at least 10 years within the next 20 years.
- Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
- Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit http://www.cancerresearchuk.org. Follow us on Twitter and Facebook.
Journal
JAMA Oncology